CymaBay Therapeutics Company Profile (NASDAQ:CBAY)

About CymaBay Therapeutics

CymaBay Therapeutics logoCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CBAY
  • CUSIP:
Key Metrics:
  • Previous Close: $2.96
  • 50 Day Moving Average: $2.15
  • 200 Day Moving Average: $1.97
  • 52-Week Range: $1.02 - $3.38
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.15
  • P/E Growth: 0.00
  • Market Cap: $69.40M
  • Outstanding Shares: 23,447,000
  • Beta: 1.17
Profitability:
  • Return on Equity: -136.00%
  • Return on Assets: -76.09%
Debt:
  • Debt-to-Equity Ratio: 0.67%
  • Current Ratio: 3.16%
  • Quick Ratio: 3.16%
Additional Links:
Companies Related to CymaBay Therapeutics:

Analyst Ratings

Consensus Ratings for CymaBay Therapeutics (NASDAQ:CBAY) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (102.70% upside)

Analysts' Ratings History for CymaBay Therapeutics (NASDAQ:CBAY)
Show:
DateFirmActionRatingPrice TargetDetails
1/30/2017HC WainwrightUpgradeNeutral -> Buy$2.50 -> $6.00View Rating Details
7/1/2016Roth CapitalInitiated CoverageBuyView Rating Details
7/21/2015Piper Jaffray CompaniesInitiated CoverageOverweight$4.00View Rating Details
5/8/2015Stifel NicolausReiterated RatingBuy$15.00 -> $9.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for CymaBay Therapeutics (NASDAQ:CBAY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2017        
5/12/2016Q1($0.28)($0.29)ViewListenView Earnings Details
3/29/2016Q4($0.35)($0.26)ViewListenView Earnings Details
11/12/2015Q315($0.33)($0.27)ViewListenView Earnings Details
8/10/2015Q215($0.42)($0.09)ViewListenView Earnings Details
5/7/2015($0.43)($0.44)ViewN/AView Earnings Details
3/18/2015Q414($0.47)($0.87)ViewN/AView Earnings Details
11/12/2014Q314($0.47)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CymaBay Therapeutics (NASDAQ:CBAY)
Current Year EPS Consensus Estimate: $-1.13 EPS
Next Year EPS Consensus Estimate: $-0.94 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.30)($0.30)($0.30)
Q3 20161($0.31)($0.31)($0.31)
Q4 20161($0.26)($0.26)($0.26)
Q1 20171($0.28)($0.28)($0.28)
Q2 20171($0.29)($0.29)($0.29)
Q3 20171($0.20)($0.20)($0.20)
Q4 20171($0.21)($0.21)($0.21)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CymaBay Therapeutics (NASDAQ:CBAY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CymaBay Therapeutics (NASDAQ:CBAY)
Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 27.88%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/6/2016Robert James WillsDirectorBuy25,000$2.43$60,750.00View SEC Filing  
4/15/2016Charles McwherterVPBuy3,000$1.68$5,040.00View SEC Filing  
4/5/2016Sujal ShahCFOBuy55,000$1.39$76,450.00View SEC Filing  
4/4/2016Sujal ShahCFOBuy22,000$1.39$30,580.00View SEC Filing  
9/11/2015Carl GoldfischerDirectorSell46,729$2.74$128,037.46View SEC Filing  
8/14/2015Emster Kurt VonDirectorBuy90,000$2.69$242,100.00View SEC Filing  
7/20/2015Emster Kurt VonDirectorBuy1,600,000$2.81$4,496,000.00View SEC Filing  
5/18/2015Sujal ShahCFOBuy10,000$3.40$34,000.00View SEC Filing  
5/18/2015Wart Harold VanCEOBuy7,500$3.34$25,050.00View SEC Filing  
5/15/2015Charles McwherterVPBuy2,000$3.16$6,320.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for CymaBay Therapeutics (NASDAQ:CBAY)
DateHeadline
News IconCymabay Therapeutics, Inc. (NASDAQ:CBAY) Hits Highs with Strength in Pipeline - StockNewsUnion (NASDAQ:CBAY)
stocknewsunion.com - February 22 at 12:14 PM
News IconAnalyst Observation On 2 Stocks: Cempra, Inc. (NASDAQ:CEMP), Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Post Analyst (NASDAQ:CBAY)
postanalyst.com - February 21 at 2:01 PM
News IconIs a Pullback Coming For Cymabay Therapeutics, Inc. (NASDAQ:CBAY)? - Aiken Advocate (NASDAQ:CBAY)
aikenadvocate.com - February 21 at 2:01 PM
News IconWhy Analysts put forward these two stocks: Evoke Pharma, Inc. (EVOK), Cymabay Therapeutics, Inc. (CBAY) - The USA Commerce (NASDAQ:CBAY)
www.theusacommerce.com - February 21 at 2:01 PM
News IconStock Price of CymaBay Therapeutics Inc. (CBAY) Increases 37.45% - Highland Mirror (NASDAQ:CBAY)
www.highlandmirror.com - February 21 at 2:01 PM
News IconStocks in Analyst's Viewfinder: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) Cohu, Inc. (NASDAQ:COHU) - Rives Journal (NASDAQ:CBAY)
rivesjournal.com - February 19 at 3:55 PM
News IconCymabay Therapeutics, Inc. (NASDAQ:CBAY) Experiencing ... - Winfield Review (NASDAQ:CBAY)
winfieldreview.com - February 19 at 11:28 AM
News IconShare Tracker: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - SKV News (NASDAQ:CBAY)
skvnews.com - February 18 at 10:10 AM
News IconThe Bears And Bulls Square Off On Cymabay Therapeutics, Inc ... - NY Stock News (NASDAQ:CBAY)
nystocknews.com - February 18 at 10:10 AM
finance.yahoo.com logoCan The Uptrend Continue for Cymabay Therapeutics (CBAY)? (NASDAQ:CBAY)
finance.yahoo.com - February 14 at 4:52 PM
finance.yahoo.com logoCerner's EHR Platform to Enhance Health Care at San Juan NGO (NASDAQ:CBAY)
finance.yahoo.com - February 13 at 4:46 PM
finance.yahoo.com logo5 Breakout Stocks for Superior Returns (NASDAQ:CBAY)
finance.yahoo.com - February 10 at 3:47 PM
finance.yahoo.com logoCymabay Therapeutics (CBAY) Rises: Stock Moves 9.2% Higher (NASDAQ:CBAY)
finance.yahoo.com - February 9 at 4:28 PM
News IconDoes CymaBay Therapeutics Inc (CBAY) Have Any Gas After Forming This Bullish Inverse H&S Pattern? (NASDAQ:CBAY)
randolphguide.com - February 6 at 4:11 PM
News IconHot Stocks Report Cymabay Therapeutics, Inc. (NASDAQ:CBAY ... - Post Analyst (NASDAQ:CBAY)
postanalyst.com - February 3 at 4:24 PM
News IconCymabay Therapeutics Inc. (NASDAQ:CBAY) showed monthly volitility of 10.62% - The Newburgh Press (NASDAQ:CBAY)
newburghpress.com - February 3 at 4:24 PM
streetinsider.com logoCymaBay Therapeutics (CBAY) Prices 5.2M Offering of Common Stock at $1.93/Share - StreetInsider.com (NASDAQ:CBAY)
www.streetinsider.com - February 3 at 4:24 PM
streetinsider.com logoCymaBay Therapeutics (CBAY) Prices 5.2M Offering of Common Stock at $1.93/Share (NASDAQ:CBAY)
www.streetinsider.com - February 2 at 4:25 PM
us.rd.yahoo.com logoCymaBay Announces Pricing of Public Offering of Common Stock (NASDAQ:CBAY)
us.rd.yahoo.com - February 2 at 4:25 PM
streetinsider.com logoCymaBay Therapeutics (CBAY) Plans Public Offering of Common Stock (NASDAQ:CBAY)
www.streetinsider.com - February 2 at 2:25 AM
streetinsider.com logoAfter-Hours Stock Movers 02/01: (MJN) (ESIO) (FB) Higher; (AVIR) (SFLY) (MLNX) Lower (more...) (NASDAQ:CBAY)
www.streetinsider.com - February 1 at 9:25 PM
us.rd.yahoo.com logo4:02 pm CymaBay Therapeutics announces that it intends to offer and sell shares of its common stock; size not disclosed (NASDAQ:CBAY)
us.rd.yahoo.com - February 1 at 9:25 PM
finance.yahoo.com logoCymaBay Announces Proposed Public Offering of Common Stock (NASDAQ:CBAY)
finance.yahoo.com - February 1 at 4:24 PM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Nelson Research (NASDAQ:CBAY)
nelsonobserver.com - February 1 at 6:42 AM
News IconStock Scrambling Higher Out of The Gate: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Aiken Advocate (NASDAQ:CBAY)
aikenadvocate.com - January 30 at 9:12 PM
News IconH.C. Wainwright Just Issued " Buy" Rating on CymaBay Therapeutics Inc (CBAY) - Highland Mirror (NASDAQ:CBAY)
www.highlandmirror.com - January 30 at 9:12 PM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Prospect Journal (NASDAQ:CBAY)
prospectjournal.com - January 30 at 4:11 PM
News IconHigh Volatility Moving the Needle For Shares of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Wall Street Beacon (NASDAQ:CBAY)
wsbeacon.com - January 30 at 4:11 PM
finance.yahoo.com logoCymaBay Therapeutics upgraded by H.C. Wainwright (NASDAQ:CBAY)
finance.yahoo.com - January 30 at 4:11 PM
News IconUnorthodox Volume Noted Mid-Session in Shares of Cymabay ... - Aiken Advocate (NASDAQ:CBAY)
aikenadvocate.com - January 27 at 5:24 PM
News IconStock Perspective: Cymabay Therapeutics Inc. (NASDAQ:CBAY) Company Earnings Watch - Aiken Advocate (NASDAQ:CBAY)
aikenadvocate.com - January 26 at 10:00 PM
News IconEarnings in Full Force, Analysts Take Aim at Cymabay Therapeutics ... - Wall Street Beacon (NASDAQ:CBAY)
wsbeacon.com - January 26 at 4:58 PM
4-traders.com logoCYMABAY THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K) (NASDAQ:CBAY)
www.4-traders.com - January 24 at 4:44 PM
4-traders.com logoCYMABAY THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K) (NASDAQ:CBAY)
www.4-traders.com - January 24 at 4:44 PM
News IconAre Insiders Filling Their Own Pockets With Shares? Insider Update on Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Wall Street Beacon (NASDAQ:CBAY)
wsbeacon.com - January 23 at 9:30 PM
News IconPriming The Pump: Stock Volatility Spotted in Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Wall Street Beacon (NASDAQ:CBAY)
wsbeacon.com - January 23 at 9:30 PM
News IconSell-side is Weighing in on Cymabay Therapeutics Inc. (NASDAQ:CBAY) Earnings & Targets - Aiken Advocate (NASDAQ:CBAY)
aikenadvocate.com - January 22 at 4:10 PM
News IconA Keen Look at These Shares: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Prospect Journal (NASDAQ:CBAY)
prospectjournal.com - January 20 at 10:23 PM
News IconStock Tracker: Earnings & Estimates for Cymabay Therapeutics Inc. (NASDAQ:CBAY) - Aiken Advocate (NASDAQ:CBAY)
aikenadvocate.com - January 20 at 3:23 AM
News IconAre Investors Shying Away from Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Prospect Journal (NASDAQ:CBAY)
prospectjournal.com - January 19 at 10:21 PM
News IconPumping the Brakes as Stock Dragged Lower Mid-Session: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Wall Street Beacon (NASDAQ:CBAY)
wsbeacon.com - January 18 at 8:38 PM
News IconShort Interest Filing: It Seems Cymabay Therapeutics Incorporated (NASDAQ:CBAY) Will Go Up. Just Reported Less ... - Baxley Report (NASDAQ:CBAY)
baxleyreport.com - January 18 at 3:38 PM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Wall Street Beacon (NASDAQ:CBAY)
wsbeacon.com - January 18 at 3:01 AM
News IconStock ready to Pivot? Focus on Shares of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Prospect Journal (NASDAQ:CBAY)
prospectjournal.com - January 18 at 3:01 AM
News IconTracking Corporate Insiders: What Are They Doing With Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Wall Street Beacon (NASDAQ:CBAY)
wsbeacon.com - January 18 at 3:01 AM
News IconStock Momentum Skidding to a Halt For Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Wall Street Beacon (NASDAQ:CBAY)
wsbeacon.com - January 18 at 3:01 AM
News IconIs There a Spark Ahead for Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Prospect Journal (NASDAQ:CBAY)
prospectjournal.com - January 12 at 9:28 PM
News IconShares Backsliding in Session: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Wall Street Beacon (NASDAQ:CBAY)
wsbeacon.com - January 12 at 9:28 PM
seekingalpha.com logoCymaBay Is Dirt Cheap, But Is It A Bargain? - Seeking Alpha - Seeking Alpha (NASDAQ:CBAY)
seekingalpha.com - January 11 at 9:34 PM
News IconAre Institutions Jumping Ship on Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Wall Street Beacon (NASDAQ:CBAY)
wsbeacon.com - January 11 at 9:34 PM

Social

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

Where is CymaBay Therapeutics' stock going? Where will CymaBay Therapeutics' stock price be in 2017?

2 brokers have issued 12-month price objectives for CymaBay Therapeutics' stock. Their predictions range from $6.00 to $6.00. On average, they anticipate CymaBay Therapeutics' share price to reach $6.00 in the next twelve months.

When will CymaBay Therapeutics announce their earnings?

CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.

Who owns CymaBay Therapeutics stock?

CymaBay Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Kingdon Capital Management L.L.C. (4.01%), J. Goldman & Co LP (1.41%) and Renaissance Technologies LLC (0.50%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Charles Mcwherter, Emster Kurt Von, Robert James Wills, Sujal Shah and Wart Harold Van.

Who sold CymaBay Therapeutics stock? Who is selling CymaBay Therapeutics stock?

CymaBay Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C. and Renaissance Technologies LLC.

Who bought CymaBay Therapeutics stock? Who is buying CymaBay Therapeutics stock?

CymaBay Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including J. Goldman & Co LP. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter, Emster Kurt Von, Robert James Wills, Sujal Shah and Wart Harold Van.

How do I buy CymaBay Therapeutics stock?

Shares of CymaBay Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of CymaBay Therapeutics stock cost?

One share of CymaBay Therapeutics stock can currently be purchased for approximately $2.96.

CymaBay Therapeutics (NASDAQ:CBAY) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Earnings History Chart

Earnings by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Dividend History Chart

Dividend Payments by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Last Updated on 2/24/2017 by MarketBeat.com Staff